Health Canada approved Lilly’s $47,250 Alzheimer’s drug Kisunla, raising new questions over public reimbursement.

CNW/ - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health ...

Health Canada has approved a second drug that targets the underlying cause of Alzheimer’s disease, a development that could ...

Alzheimer’s Research UK says patients at risk of being left behind as lack of formal or accurate diagnoses closes door to trials ...

This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved ...

Health Canada has approved Eli Lilly’s donanemab, branded as Kisunla, as the country’s second Alzheimer’s drug shown to slow disease progression. The therapy targets amyloid plaques and is intended ...

A drug that may slow progression of dementia in some patients has been approved for use in Canada, the manufacturer announced.

Alzheimer's Disease," Cleveland Clinic behavioral neurologist Jagan Pillai, MD, PhD, and host Glenn Campbell continue their ...

Health Canada has approved Eli Lilly’s donanemab, sold as Kisunla, as the second Alzheimer’s drug in Canada proven to slow disease progression by targeting amyloid plaques. The once-monthly therapy is ...

An alternate dosing plan for the anti-amyloid drug donanemab (Kisunla) reduced the risk of brain edema and effusion but still maintained sufficient amyloid reduction in early Alzheimer's disease, the ...

The European Medicines Agency (EMA) has recommended refusal of a marketing authorization for donanemab, which targets the treatment of early Alzheimer’s disease (AD). The agency's Committee for ...